---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023224"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:05:49.255920+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio Q3 net loss $22M; ADI-001 shows 78% ORR/CR, pivotal program planned H1 2023

## Summary
- Net loss of $22.0M ($0.53 per share) vs $14.0M in Q3 2021; R&D expenses rose to $16.6M.
- Cash and cash equivalents $282.7M as of Sep 30, 2022; runway into first half of 2025.
- ADI-001 Phase 1 data: 78% ORR and CR (7/9) in relapsed/refractory B-cell NHL; 100% in prior CAR-T patients.
- Expects to initiate a potentially pivotal program for ADI-001 in the first half of 2023.
- In-house manufacturing in Redwood City expected operational in Q4 2022; R&D webcast Nov 10, ASH update Dec 11.

## SEC filing metadata
- accession: 0000950170-22-023224
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017022023224/0000950170-22-023224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017022023224/acet-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023224
- JSON: https://secwatch.observer/filing/0000950170-22-023224.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023224.txt

## Key facts
- Earnings Releases
  Adicet Bio, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss for the three months ended September 30, 2022 was $22.0 million, or a net loss of $0.53 per basic and diluted s, EPS net loss of $0.53 per basic and diluted share.
  - Period: the third quarter ended September 30, 2022
  - Net income: Net loss for the three months ended September 30, 2022 was $22.0 million, or a net loss of $0.53 per basic and diluted s
  - EPS: net loss of $0.53 per basic and diluted share
  - Result: reported results
  source text: Net loss for the three months ended September 30, 2022 was $22.0 million, or a net loss of $0.53 per basic and diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720580/000095017022023224/0000950170-22-023224-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.